Second Clinical Medical College, Binzhou Medical University, Yantai, Shandong, China.
Department of Neurology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China.
Eur J Med Res. 2022 Feb 7;27(1):22. doi: 10.1186/s40001-022-00646-7.
Chorea-acanthocytosis (ChAc), as the most common subtype of neuroacanthocytosis syndrome, is characterized by the presence of acanthocytes and neurological symptoms. It is thought to be caused by the VPS13A (vacuolar protein sorting-associated protein 13A) mutations. This article reports two confirmed cases of ChAc and summarizes some suggestive features, which provide direction for the diagnosis and treatment of acanthocytosis in the future.
Here, we present two cases of ChAc diagnosed based on typical clinical symptoms, neuroimaging features, genetic findings of VPS13A, and response to the symptomatic treatment.
Chorea-acanthocytosis is a rare neurodegenerative disease with various early clinical manifestations. The final diagnosis of the ChAc can be established by either genetic analysis or protein expression by Western blotting. Supportive treatments and nursing are helpful to improve the quality of the patient's life. Nevertheless, it is imperative to investigate the impact of neuroimaging and neuropathological diagnosis in a larger group of ChAc in future studies.
棘红细胞增多性舞蹈病(ChAc)是神经棘红细胞增多症综合征中最常见的亚型,其特征为存在棘红细胞和神经症状。据认为,它是由 VPS13A(液泡蛋白分选相关蛋白 13A)突变引起的。本文报告了两例确诊的 ChAc,并总结了一些提示性特征,为今后棘红细胞增多症的诊断和治疗提供了方向。
在此,我们介绍了两例根据典型临床症状、神经影像学特征、VPS13A 的基因发现以及对症状治疗的反应诊断为 ChAc 的病例。
棘红细胞增多性舞蹈病是一种罕见的神经退行性疾病,具有多种早期临床表现。ChAc 的最终诊断可以通过基因分析或 Western blot 检测蛋白表达来确定。支持性治疗和护理有助于提高患者的生活质量。然而,在未来的研究中,有必要研究神经影像学和神经病理学诊断对更大一组 ChAc 的影响。